Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $993.5 million.

  • Collegium Pharmaceutical's Non-Current Assets fell 1661.03% to $993.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 4825.74%. This contributed to the annual value of $1.2 billion for FY2024, which is 9503.36% up from last year.
  • Collegium Pharmaceutical's Non-Current Assets amounted to $993.5 million in Q3 2025, which was down 1661.03% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Non-Current Assets peaked at $1.2 billion during Q3 2024, and registered a low of $349.8 million during Q1 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Non-Current Assets value was $716.0 million (recorded in 2023), while the average stood at $738.9 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Non-Current Assets skyrocketed by 15232.11% in 2022, and later tumbled by 1971.95% in 2024.
  • Collegium Pharmaceutical's Non-Current Assets (Quarter) stood at $376.5 million in 2021, then soared by 100.29% to $754.1 million in 2022, then fell by 19.68% to $605.7 million in 2023, then surged by 95.03% to $1.2 billion in 2024, then decreased by 15.9% to $993.5 million in 2025.
  • Its last three reported values are $993.5 million in Q3 2025, $1.0 billion for Q2 2025, and $1.1 billion during Q1 2025.